[
  {
    "trial": "T009",
    "source": "library",
    "arms": {
      "Ketamine": {"randomized": "26", "analysed": "26"},
      "Placebo (0.9% saline)": {"randomized": "26", "analysed": "26"}
    },
    "depression": [
      {"measure": "Geriatric Depression Scale 15-item", "day": -1, "form": "median_iqr", "location": "Table 3 (GDS-15, Baseline)",
       "values": {"Ketamine": {"median": "3", "q1": "0", "q3": "4", "n": "26"}, "Placebo (0.9% saline)": {"median": "2", "q1": "0", "q3": "3", "n": "26"}}},
      {"measure": "Geriatric Depression Scale 15-item", "day": 7, "form": "median_iqr", "location": "Table 3 (GDS-15, 1 Week)",
       "values": {"Ketamine": {"median": "2", "q1": "1", "q3": "3", "n": "26"}, "Placebo (0.9% saline)": {"median": "2", "q1": "1", "q3": "2", "n": "26"}}}
    ],
    "pain": [
      {"measure": "Morphine consumption (mg)", "day": 1, "form": "median_iqr", "location": "Table 2 (Morphine consumption, post-operative day 1 (mg))",
       "values": {"Ketamine": {"median": "15", "q1": "8", "q3": "22", "n": "26"}, "Placebo (0.9% saline)": {"median": "15", "q1": "8", "q3": "24", "n": "26"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2007-02", "end": "2008-03"},
    "registration": null,
    "note": "Library copy repeats sections; the repeated tables agree. GDS-15 is median (interquartile range) in Table 3, whose header gives n = 26 per column. Follow-up was '1 week after surgery (or at discharge, whichever came first)', entered as day 7. Nonsurgical controls (n = 26, not randomized) left out. The design lists no pain measure; Table 2's morphine consumption on post-operative day 1 (median (IQR), mg) is entered under the source's name; day-of-surgery morphine (Placebo 20 (10-24), Ketamine 15 (10-20)) left out as day 0. Table 1 lists a history of depression (Placebo 5 (19%), Ketamine 6 (23%)) as a comorbidity; not entered as a depression measure. No adverse-event counts, blinding check, or registration number reported; the Discussion says the anesthesiologist who opened the envelope was not blinded."
  },
  {
    "trial": "T041",
    "source": "fulltext",
    "arms": {
      "Group E": {"randomized": "142", "analysed": "108"},
      "Group C": {"randomized": "142", "analysed": "101"}
    },
    "depression": [
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": -1, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3 (baseline)",
       "values": {"Group E": {"events": "32", "n": "108"}, "Group C": {"events": "37", "n": "101"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 3, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3 (PD3)",
       "values": {"Group E": {"events": "55", "n": "102"}, "Group C": {"events": "67", "n": "99"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 7, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3 (PD7)",
       "values": {"Group E": {"events": "26", "n": "99"}, "Group C": {"events": "46", "n": "96"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 90, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3 (PD90)",
       "values": {"Group E": {"events": "11", "n": "83"}, "Group C": {"events": "25", "n": "88"}}}
    ],
    "pain": [
      {"measure": "Postoperative exercise NRS score", "day": 1, "form": "mean_sd", "location": "Table 4 (NRS-scores at postoperative day 1)",
       "values": {"Group E": {"mean": "2.67", "sd": "0.97", "n": "108"}, "Group C": {"mean": "2.84", "sd": "0.86", "n": "101"}}},
      {"measure": "Postoperative exercise NRS score", "day": 2, "form": "mean_sd", "location": "Table 4 (NRS-scores at postoperative day 2)",
       "values": {"Group E": {"mean": "2.25", "sd": "1.00", "n": "108"}, "Group C": {"mean": "2.46", "sd": "0.88", "n": "101"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"Group E": {"dizziness": "16", "nightmare": "3", "hallucination": "0"}, "Group C": {"dizziness": "10", "nightmare": "1", "hallucination": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-08-01", "end": "2023-08-30"},
    "registration": {"number": "ChiCTR2300069249", "registry": "Chinese Clinical Trial Registry", "date": null},
    "note": "Depression is reported only as counts of 'depressive symptoms' (HAMD-17 ≥ 7, Methods 2.5) with per-time denominators in Table 3; mean HAMD scores at days 3, 7 and 90 are only in Figure 3 with no printed values, not extracted. Table 1 'Preoperative depressive symptoms' 32 (29.6) vs 37 (36.6) repeats the Table 3 baseline. Randomized 142 per arm (284 consented and allocated); analysed is the Table 1/Table 4 column N (108, 101) after 34 and 41 withdrawals. The design lists no pain measure; Table 4's exercise NRS scores (mean (SD)) on postoperative days 1 and 2 are entered under the source's name; day 3 left out; analgesic pump press counts and dezocine rescue have no time point and are left out. Adverse events are 'postoperative in-hospitalization' events (Table 5); nausea, vomiting and cystitis not coded. Enrollment dates are from Methods ('carried out ... from August 1, 2022 to August 30, 2023'); Results give none. Registration date not given."
  },
  {
    "trial": "T049",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "78", "analysed": "75"},
      "Normal saline group": {"randomized": "78", "analysed": "76"}
    },
    "depression": [
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": -1, "form": "count", "definition": "BDI-II ≥ 14 (depressive symptoms; 0-13 absent)", "location": "Table 1 (Depressive symptoms at 1 day before surgery)",
       "values": {"Esketamine group": {"events": "0", "n": "78"}, "Normal saline group": {"events": "2", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 2, "form": "median_iqr", "location": "Table 3 (BDI-II score at 48 h postoperatively)",
       "values": {"Esketamine group": {"median": "6", "q1": "5", "q3": "8", "n": "78"}, "Normal saline group": {"median": "6", "q1": "5", "q3": "8", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 2, "form": "count", "definition": "BDI-II ≥ 14 (depressive symptoms; 0-13 absent)", "location": "Table 3 (Depressive symptoms at 48 h postoperatively)",
       "values": {"Esketamine group": {"events": "0", "n": "78"}, "Normal saline group": {"events": "1", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 30, "form": "median_iqr", "location": "Table 3 (BDI-II score at 1 month postoperatively)",
       "values": {"Esketamine group": {"median": "5", "q1": "4", "q3": "7", "n": "75"}, "Normal saline group": {"median": "5", "q1": "4", "q3": "8", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 30, "form": "count", "definition": "BDI-II ≥ 14 (depressive symptoms; 0-13 absent)", "location": "Table 3 (primary outcome, modified intention-to-treat population)",
       "values": {"Esketamine group": {"events": "1", "n": "75"}, "Normal saline group": {"events": "9", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 90, "form": "median_iqr", "location": "Table 3 (BDI-II score at 3 months postoperatively)",
       "values": {"Esketamine group": {"median": "1.5", "q1": "0", "q3": "4", "n": "74"}, "Normal saline group": {"median": "2", "q1": "0", "q3": "5", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 90, "form": "count", "definition": "BDI-II ≥ 14 (depressive symptoms; 0-13 absent)", "location": "Table 3 (Depressive symptoms at 3 months postoperatively)",
       "values": {"Esketamine group": {"events": "0", "n": "74"}, "Normal saline group": {"events": "1", "n": "76"}}}
    ],
    "pain": [
      {"measure": "VAS at rest", "day": 1, "form": "median_iqr", "location": "Table 2 (VAS at rest at 24 h postoperatively)",
       "values": {"Esketamine group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}, "Normal saline group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}}},
      {"measure": "VAS at rest", "day": 2, "form": "median_iqr", "location": "Table 2 (VAS at rest at 48 h postoperatively)",
       "values": {"Esketamine group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}, "Normal saline group": {"median": "0", "q1": "0", "q3": "0", "n": "78"}}},
      {"measure": "VAS on coughing", "day": 1, "form": "median_iqr", "location": "Table 2 (VAS on coughing at 24 h postoperatively)",
       "values": {"Esketamine group": {"median": "3", "q1": "0", "q3": "5", "n": "78"}, "Normal saline group": {"median": "3", "q1": "2", "q3": "5", "n": "78"}}},
      {"measure": "VAS on coughing", "day": 2, "form": "median_iqr", "location": "Table 2 (VAS on coughing at 48 h postoperatively)",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "6", "n": "78"}, "Normal saline group": {"median": "3", "q1": "2", "q3": "4", "n": "78"}}},
      {"measure": "PCIA sufentanil consumption 0-24 and 0-48 h", "day": 1, "form": "median_iqr", "location": "Table 2 (Sufentanil 0-24 h after surgery, μg)",
       "values": {"Esketamine group": {"median": "42.2", "q1": "37.8", "q3": "52.5", "n": "78"}, "Normal saline group": {"median": "42", "q1": "38.5", "q3": "49.3", "n": "78"}}},
      {"measure": "PCIA sufentanil consumption 0-24 and 0-48 h", "day": 2, "form": "median_iqr", "location": "Table 2 (Sufentanil 0-48 h after surgery, μg)",
       "values": {"Esketamine group": {"median": "87.8", "q1": "77.1", "q3": "101.6", "n": "78"}, "Normal saline group": {"median": "85.2", "q1": "78.1", "q3": "99.4", "n": "78"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"Esketamine group": {"nightmare": "1", "dizziness": "18", "visual": "1", "dissociation": "0"}, "Normal saline group": {"nightmare": "4", "dizziness": "17", "visual": "2", "dissociation": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2021-05-18", "end": "2022-05-30"},
    "registration": {"number": null, "registry": "Chinese Clinical Trial Registry", "date": "2021-05-09"},
    "note": "Table 1-3 rows without their own n take the column header n (78); rows printing '(n = ...)' use that. The cutoff for 'depressive symptoms' is not stated directly: Methods give BDI-II bands 0-13 absent, 14-19 mild, 20-28 moderate, 29-63 severe, so the definition is entered as ≥ 14. Both the score (median, IQR) and the count are entered at days 2, 30 and 90; no baseline BDI-II score is printed, only the count. Hospital discharge (no fixed day; median postoperative stay 4 vs 5 days) left out: BDI-II 6 (5, 7) vs 6 (5, 8) and depressive symptoms 0 vs 4 (5.1%) (Esketamine vs Normal saline, Table 3). Day 30 count is the modified ITT population; excluding patients without lung cancer it is 1/72 vs 9/74. The text gives p = 0.664 for the 1-month BDI-II comparison where Table 3 gives 0.644 (p-values not extracted). Sufentanil is cumulative over 0-24 h (day 1) and 0-48 h (day 2). Adverse events are within 0-48 h postoperatively; blurred vision coded as visual; delirium 0 vs 0 and PONV 34 vs 34 not coded. No registration number printed; Methods say it was registered on the Chinese Clinical Trial Registry on May 9, 2021, before the first participant."
  },
  {
    "trial": "T053",
    "source": "fulltext",
    "arms": {
      "Group S": {"randomized": null, "analysed": "53"},
      "Group P": {"randomized": null, "analysed": "53"}
    },
    "depression": [
      {"measure": "Hamilton Depression Scale (HAMD)", "day": -1, "form": "mean_sd", "location": "Table 3 (HAMD, Pre)",
       "values": {"Group S": {"mean": "10.0", "sd": "2.8", "n": null}, "Group P": {"mean": "9.6", "sd": "3.0", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 3, "form": "mean_sd", "location": "Table 3 (HAMD, 72h)",
       "values": {"Group S": {"mean": "9.0", "sd": "1.8", "n": null}, "Group P": {"mean": "9.3", "sd": "2.9", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 7, "form": "mean_sd", "location": "Table 3 (HAMD, 7d)",
       "values": {"Group S": {"mean": "9.8", "sd": "1.6", "n": null}, "Group P": {"mean": "9.1", "sd": "2.7", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 30, "form": "mean_sd", "location": "Table 3 (HAMD, 30d)",
       "values": {"Group S": {"mean": "9.8", "sd": "2.6", "n": null}, "Group P": {"mean": "10.0", "sd": "3.0", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS pain", "day": 1, "form": "median_iqr", "location": "Table 3 (NRS, 24h)",
       "values": {"Group S": {"median": "2", "q1": "2", "q3": "4", "n": null}, "Group P": {"median": "3", "q1": "2", "q3": "4.5", "n": null}}},
      {"measure": "NRS pain", "day": 2, "form": "median_iqr", "location": "Table 3 (NRS, 48h)",
       "values": {"Group S": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Group P": {"median": "2", "q1": "1", "q3": "3", "n": null}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-04", "end": "2022-07"},
    "registration": {"number": "ChiCTR2100049857", "registry": "Chinese Clinical Trial Registry", "date": null},
    "note": "Randomized numbers per arm are not printed (the flowchart is not in the text): 118 women enrolled, 4 with surgery cancelled and 8 with changed surgical modality excluded, 106 completed (53 per group), so analysed = 53. Table 3 prints no n per time point. HAMD version not stated; mean ± SD; 7- and 30-day scores collected by telephone; 72 h entered as day 3. NRS at 8 h, 72 h, 7 d, 30 d and 10 min after extubation (Table 2) left out (not day 1 or 2). Adverse reactions are only in Supplementary Table S1 (not available); none extracted. Single-blind per Methods. Enrollment dates are from Methods ('recruited ... from April 2022 to July 2022'); Results give none. Registered 'before subject enrolment'; date not given."
  },
  {
    "trial": "T065",
    "source": "fulltext",
    "arms": {
      "Esketamine group (Group E)": {"randomized": "32", "analysed": "32"},
      "Control group (Group C)": {"randomized": "32", "analysed": "32"}
    },
    "depression": [
      {"measure": "PHQ-9", "day": -1, "form": "mean_sd", "location": "Table 3 (PHQ-9 score, Before)",
       "values": {"Esketamine group (Group E)": {"mean": "3.22", "sd": "3.44", "n": null}, "Control group (Group C)": {"mean": "3.28", "sd": "3.15", "n": null}}},
      {"measure": "PHQ-9", "day": 1, "form": "mean_sd", "location": "Table 3 (PHQ-9 score, POD 1)",
       "values": {"Esketamine group (Group E)": {"mean": "2.19", "sd": "2.75", "n": null}, "Control group (Group C)": {"mean": "4.03", "sd": "3.84", "n": null}}},
      {"measure": "PHQ-9", "day": 3, "form": "mean_sd", "location": "Table 3 (PHQ-9 score, POD 3)",
       "values": {"Esketamine group (Group E)": {"mean": "2.56", "sd": "3.27", "n": null}, "Control group (Group C)": {"mean": "3.25", "sd": "2.71", "n": null}}},
      {"measure": "PHQ-9", "day": 7, "form": "mean_sd", "location": "Table 3 (PHQ-9 score, POD 7)",
       "values": {"Esketamine group (Group E)": {"mean": "1.91", "sd": "2.26", "n": null}, "Control group (Group C)": {"mean": "3.16", "sd": "2.94", "n": null}}},
      {"measure": "PHQ-9", "day": 30, "form": "mean_sd", "location": "Table 3 (PHQ-9 score, POD 30)",
       "values": {"Esketamine group (Group E)": {"mean": "1.72", "sd": "2.05", "n": null}, "Control group (Group C)": {"mean": "2.44", "sd": "2.94", "n": null}}}
    ],
    "pain": [
      {"measure": "VAS pain score", "day": 1, "form": "mean_sd", "location": "Table 3 (VAS score, POD 1)",
       "values": {"Esketamine group (Group E)": {"mean": "1.28", "sd": "1.97", "n": null}, "Control group (Group C)": {"mean": "1.22", "sd": "1.70", "n": null}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-05", "end": "2023-03"},
    "registration": null,
    "note": "Tables list the Control group first; values assigned by column. Table 3 prints no n per time point; Results say 32 per arm were analysed and no participant missed follow-up. Table 3 '±' read as SD (Statistical analysis: 'mean ± SD'); Figures 4 and 5 show mean and SE and were not used. VAS also reported before surgery and on POD 3, 7 and 30 (left out; pain only at days 1 and 2); no day-2 VAS. Intraoperative remifentanil (Table 2: Control 513.0 ± 179.9, Esketamine 489.9 ± 175.6 ug) is day 0, left out. Only nausea (6 vs 6), vomiting (3 vs 2) and delirium (0 vs 0) reported as complications (Control vs Esketamine), none coded; 2 patients per group needed rescue tramadol. Enrollment dates are from Methods ('between May 2022 and March 2023'); Results give none. No registration number in the text."
  },
  {
    "trial": "T081",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "71", "analysed": "71"},
      "Saline control group": {"randomized": "71", "analysed": "71"}
    },
    "depression": [
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": -1, "form": "count", "definition": "HADS-D ≥ 8 (0-7 normal)", "location": "Table 2 (Preoperative assessments, Depression)",
       "values": {"Esketamine group": {"events": "26", "n": "71"}, "Saline control group": {"events": "25", "n": "71"}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 7, "form": "count", "definition": "HADS-D ≥ 8 (0-7 normal)", "location": "Table 3 (Depression at POD 7)",
       "values": {"Esketamine group": {"events": "5", "n": "71"}, "Saline control group": {"events": "22", "n": "71"}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 7, "form": "difference", "location": "Results 3.2, text (post hoc linear mixed-effects model, Sidak-adjusted)",
       "estimate": "1.61", "lower": "0.40", "upper": "2.82", "level": "0.95", "scale": "mean_difference",
       "values": {"Esketamine group": {"n": null}, "Saline control group": {"n": null}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 30, "form": "count", "definition": "HADS-D ≥ 8 (0-7 normal)", "location": "Table 3 (POD 30, Depression)",
       "values": {"Esketamine group": {"events": "0", "n": "71"}, "Saline control group": {"events": "3", "n": "71"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "values": {"Esketamine group": {"psychiatric_any": "13", "visual": "1"}, "Saline control group": {"psychiatric_any": "6", "visual": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-09-23", "end": "2025-03"},
    "registration": {"number": "NCT06608030", "registry": "ClinicalTrials.gov", "date": null},
    "note": "Tables list the Control group first. Baseline depression: Table 2 gives Control 25 (35.2), Esketamine 26 (36.6), but the Results text says 25/71 in the esketamine group vs 26/71 in controls (anxiety is swapped the same way); the table's values are entered. The cutoff for 'depression' is not stated; Methods give HADS bands 0-7 normal, 8-10 mild, 11-14 moderate, ≥15 severe, so ≥ 8 is entered. Counts are ITT with n = 71 per arm although 4 per arm lost the primary endpoint (per-protocol results only in Supplementary Table S3). HADS-D mean scores are only in Supplementary Fig. S4/Table S8; the day-7 difference is the printed 'MD [SEM] 1.61 [0.61], 95 % CI 0.40-2.82' for a decrease in the esketamine group vs control, i.e. control minus esketamine; arm n not given. NRS pain is reported only at POD 7 and POD 30, left out. Adverse events are drug-related side effects within 3 days: 'Hallucination or nightmares' (one combined count) coded as psychiatric_any; 'Nystagmus, blurred vision' as visual. Delirium within 7 days (7 vs 16; hyperactive 2 vs 4, Esketamine vs Control) not coded. Enrollment dates are from Methods (September 2024 to March 2025; first patient 23 September 2024); Results give none. NCT06608030 registered before enrolment; date not given."
  },
  {
    "trial": "T089",
    "source": "fulltext",
    "arms": {
      "Esk group": {"randomized": "44", "analysed": "41"},
      "NS group": {"randomized": "44", "analysed": "41"}
    },
    "depression": [
      {"measure": "HAMD-17", "day": -1, "form": "median_iqr", "location": "Table 1 (Evaluation scores 1 day before surgery, HAMD-17)",
       "values": {"Esk group": {"median": "6", "q1": "5", "q3": "7", "n": "41"}, "NS group": {"median": "6", "q1": "5", "q3": "7", "n": "41"}}},
      {"measure": "HAMD-17", "day": 7, "form": "median_iqr", "location": "Table 2 (HAMD-17 score, 7 d after surgery)",
       "values": {"Esk group": {"median": "7", "q1": "6", "q3": "8", "n": "41"}, "NS group": {"median": "7", "q1": "6", "q3": "12", "n": "41"}}},
      {"measure": "HAMD-17", "day": 30, "form": "median_iqr", "location": "Table 2 (HAMD-17 score, 30 d after surgery)",
       "values": {"Esk group": {"median": "6", "q1": "6", "q3": "7", "n": "41"}, "NS group": {"median": "7", "q1": "6", "q3": "9", "n": "41"}}}
    ],
    "pain": [
      {"measure": "NRS at rest (24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 4 (Pain scores at rest (NRS), At 24 h)",
       "values": {"Esk group": {"median": "2", "q1": "0", "q3": "2", "n": "41"}, "NS group": {"median": "2", "q1": "0", "q3": "3", "n": "41"}}},
      {"measure": "NRS at rest (24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 4 (Pain scores at rest (NRS), At 48 h)",
       "values": {"Esk group": {"median": "0", "q1": "0", "q3": "1", "n": "41"}, "NS group": {"median": "0", "q1": "0", "q3": "1", "n": "41"}}},
      {"measure": "NRS on coughing (24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 4 (Pain scores while coughing (NRS), At 24 h)",
       "values": {"Esk group": {"median": "3", "q1": "1", "q3": "4", "n": "41"}, "NS group": {"median": "3", "q1": "1", "q3": "4", "n": "41"}}},
      {"measure": "NRS on coughing (24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 4 (Pain scores while coughing (NRS), At 48 h)",
       "values": {"Esk group": {"median": "1", "q1": "0", "q3": "2", "n": "41"}, "NS group": {"median": "1", "q1": "0", "q3": "3", "n": "41"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"Esk group": {"psychiatric_any": "1", "dizziness": "3", "agitation": "0"}, "NS group": {"psychiatric_any": "1", "dizziness": "2", "agitation": "1"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-08", "end": "2024-06"},
    "registration": null,
    "note": "Chinese full text with English tables. 88 randomized, 44 per group; 3 per group excluded after randomization (Esk: conversion to thoracotomy, benign pathology, family refused phone follow-up; NS: reoperation for bleeding, wedge resection, benign pathology), leaving 41 per group. HAMD-17 is median (P25, P75); Methods define depression as HAMD-17 ≥ 8 but no counts are reported. The Results text repeats the day 7 and 30 values with a stray 'd' unit. Safety outcomes (Table 4, n = 41 per group) are postoperative with no narrower window: 'Hallucination or nightmare' (one combined count) coded as psychiatric_any; 'Headache or dizziness' (one combined count) coded as dizziness; 'Agitation' (listed with delayed recovery, possibly emergence agitation) coded as agitation. Enrollment dates are from Methods (August 2023 to June 2024); Results give none. No registration number in the text."
  },
  {
    "trial": "T095",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "154", "analysed": "154"},
      "Control group": {"randomized": "154", "analysed": "154"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "median_iqr", "location": "Table 1 (Baseline EPDS scores)",
       "values": {"Esketamine group": {"median": "5", "q1": "2", "q3": "10", "n": "154"}, "Control group": {"median": "5", "q1": "2", "q3": "9", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "median_iqr", "location": "Table 2 (EPDS scores, 1 wk)",
       "values": {"Esketamine group": {"median": "5", "q1": "1.75", "q3": "8", "n": "154"}, "Control group": {"median": "5", "q1": "3", "q3": "9", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "count", "definition": "EPDS > 10 (positive PPD screening)", "location": "Table 2 (PPD, 1 wk)",
       "values": {"Esketamine group": {"events": "24", "n": "154"}, "Control group": {"events": "37", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "median_iqr", "location": "Table 2 (EPDS scores, 6 wk)",
       "values": {"Esketamine group": {"median": "5", "q1": "2", "q3": "7", "n": "154"}, "Control group": {"median": "6", "q1": "3", "q3": "9", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "count", "definition": "EPDS > 10 (positive PPD screening)", "location": "Table 2 (PPD, 6 wk)",
       "values": {"Esketamine group": {"events": "16", "n": "154"}, "Control group": {"events": "30", "n": "154"}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2A)",
       "values": {"Esketamine group": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Control group": {"median": "1", "q1": "1", "q3": "2", "n": null}}},
      {"measure": "NRS at rest", "day": 2, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2A)",
       "values": {"Esketamine group": {"median": "1", "q1": "1", "q3": "1", "n": null}, "Control group": {"median": "1", "q1": "0.75", "q3": "1", "n": null}}},
      {"measure": "NRS with movement", "day": 1, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2B)",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "3", "n": null}, "Control group": {"median": "3", "q1": "3", "q3": "3", "n": null}}},
      {"measure": "NRS with movement", "day": 2, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2B)",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "3", "n": null}, "Control group": {"median": "2", "q1": "2", "q3": "3", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "values": {"Esketamine group": {"dizziness": "28", "dissociation": "9", "hallucination": "4", "nightmare": "16", "visual": "1", "any_ae": "65"}, "Control group": {"dizziness": "3", "dissociation": "0", "hallucination": "0", "nightmare": "0", "visual": "0", "any_ae": "12"}}},
      {"window": "postoperative", "values": {"Esketamine group": {"dizziness": "8", "any_ae": "23"}, "Control group": {"dizziness": "5", "any_ae": "14"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-03", "end": "2024-02"},
    "registration": null,
    "note": "Esketamine was infused after fetal delivery under neuraxial anaesthesia; 1 wk entered as day 7, 6 wk as day 42. PPD is defined in Methods and table footnotes as EPDS > 10, but the analysis text calls the usual cutoff '10 or higher' and the sensitivity analysis's '≥11' counts (1 wk 24 vs 31; 6 wk 13 vs 24) differ from the PPD counts, so the primary cutoff may be ≥ 10. Other sensitivity cutoffs (Table 2, Esketamine vs Control, n = 154): ≥9: 1 wk 32 vs 41, 6 wk 26 vs 45; ≥12: 1 wk 15 vs 23, 6 wk 8 vs 18. Table 1 'Antenatal depression' 42 (27.3) vs 36 (23.4) has no stated definition; not entered. Pain medians [IQR] are from the Results text (Figure 2 is a box plot) with no n; POD 3 left out. PCIA total consumption (75.55 [5.81] vs 76.40 [6.06] mL) and bolus counts have no 24/48-h time point; left out. Adverse events 'at end of surgery' (open-ended inquiry about events during surgery) coded as intraoperative: 'Mental trance state' (narrowed awareness, altered consciousness) coded as dissociation, 'Dreamscape' (a dream during surgery) as nightmare, 'Diplopia' as visual, 'Total' as any_ae. 'Within 3 d post partum' coded as postoperative. From 3 d to 6 wk post partum: anxiety 7 vs 2 and total 16 vs 9, not entered. Enrollment dates are from Methods (March 2023 to February 2024); Results give none. No registration number in the text."
  },
  {
    "trial": "T104",
    "source": "fulltext",
    "arms": {
      "N group (saline)": {"randomized": "35", "analysed": null},
      "A group (esketamine)": {"randomized": "35", "analysed": null}
    },
    "depression": [
      {"measure": "Zung SDS", "day": -1, "form": "mean_sd", "location": "Table 3 (SDS score, baseline; same values in Table 1)",
       "values": {"N group (saline)": {"mean": "46.0", "sd": "8.7", "n": null}, "A group (esketamine)": {"mean": "46.0", "sd": "8.2", "n": null}}},
      {"measure": "Zung SDS", "day": 1, "form": "mean_sd", "location": "Table 3 (SDS score, POD1)",
       "values": {"N group (saline)": {"mean": "52.5", "sd": "9.7", "n": null}, "A group (esketamine)": {"mean": "49.0", "sd": "8.8", "n": null}}},
      {"measure": "Zung SDS", "day": 2, "form": "mean_sd", "location": "Table 3 (SDS score, POD2)",
       "values": {"N group (saline)": {"mean": "50.0", "sd": "9.0", "n": null}, "A group (esketamine)": {"mean": "47.5", "sd": "8.4", "n": null}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "emergence", "values": {"N group (saline)": {"agitation": "11"}, "A group (esketamine)": {"agitation": "8"}}},
      {"window": "postoperative", "values": {"N group (saline)": {"psychiatric_any": "0"}, "A group (esketamine)": {"psychiatric_any": "5"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-05", "end": "2025-12"},
    "registration": null,
    "note": "Secondary analysis of a four-arm randomized study (LA, L, A, N; 35 each); only A and N entered. Tables list columns LA, L, A, N. All 140 were in the safety analysis (adverse-event denominators 35), but efficacy analyses used endpoint-specific observed data and no SDS denominators are printed, so analysed and n are left blank (QoR-40 POD1 n: A 35, N 34; POD7: A 34, N 34). SDS is the standardized Zung score (raw × 1.25); POD1 = 24 ± 6 h and POD2 = 48 ± 6 h after extubation. The QoR-40 pain dimension is only in Supplementary Table S1 (not available), so no pain data. Emergence agitation is Riker ≥ 5 in the PACU. 'Vivid dreams/hallucinations' (one combined count, PACU and POD1) coded as psychiatric_any. Nu-DESC PACU delirium-like symptoms (A 3 (8.6%), N 4 (11.4%)) not coded; perioral numbness/tinnitus 0 vs 0. Blinding success was not formally assessed. Enrollment dates are the parent study's period from Methods (May 2024 to December 2025); Results give none. No registration number in the text."
  }
]